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Abstract 
Objective
To describe the efficacy, safety, and exposure-response relationship of canakinumab in a subgroup of patients with 
systemic juvenile idiopathic arthritis (SJIA) aged ≥16 years, representative of adult-onset Still’s disease (AOSD) patients, 
and to compare this subgroup with those of children and young adolescents with SJIA by pooling clinical data collected 
during the development programme of canakinumab.
Methods
Safety and efficacy data on canakinumab-treated patients were pooled from 4 SJIA studies (NCT00426218, NCT00886769, 
NCT00889863, and NCT00891046). In the majority of patients, canakinumab was administered at 4 mg/kg every 4 weeks. 
Efficacy parameters (adapted American College of Rheumatology [aACR] paediatric and juvenile idiopathic arthritis [JIA] 
ACR responses), quality of life, C-reactive protein levels, safety, and exposure-response relationship were assessed over 12 
weeks in 3 age groups (children 2–<12, young adolescents 12–<16 and older adolescents and young adults ≥16 years). 
Results
Efficacy outcomes were analysed in 216 children, 56 young adolescents and 29 older adolescents and young adults. 
Efficacy parameters across 3 age groups were largely comparable. At Day 15, at least 50% of patients from each age 
group exhibited aACR ≥70 and ACR responses. The safety profile of canakinumab was similar across age groups. 
One death was reported. 
Conclusions
Pooled analyses from SJIA studies indicate that older adolescents and young adults SJIA patients show similar efficacy, 
safety, and exposure-response relationship on a weight-based dosing regimen as observed in children and adolescent SJIA 
patients. These analyses suggest that canakinumab may be an effective therapy in young adults with Still’s disease.
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Introduction
Still’s disease presents in paediatric and 
adult patients as a disease continuum 
with similar pathophysiology and is 
denoted as systemic juvenile idiopathic 
arthritis (SJIA) and adult-onset Still’s 
disease (AOSD), respectively (1-2). 
SJIA and AOSD are both rare systemic 
inflammatory diseases that share simi-
lar clinical symptoms including spiking 
fever, skin rash, arthralgia or arthritis, 
myalgia, hepatosplenomegaly, lym-
phadenopathy, serositis and laboratory 
findings with acute-phase response, hy-
perferritinemia and leukocytosis (3-5).
SJIA and AOSD have cytokine-driven 
pathologies wherein interleukin-1 (IL-
1) plays a key role (1). The pathophysi-
ology of these diseases is complex due 
to abnormal activation of the innate 
immune response with induction of a 
cytokine cascade (Th1) (6-7) and el-
evation of IL-8, IL-6, tumour necrosis 
factor (TNF)-α, and IL-17, which are 
downstream of IL-1β and IL-18 (1). The 
key role of IL-1β in SJIA was estab-
lished in studies that analysed patterns 
of gene transcription in peripheral blood 
mononuclear cells (PBMCs) (8-11). In 
addition, IL-1β is elevated in the serum 
of SJIA and AOSD patients (1, 12). 
Blockade of the IL-1 pathway is an 
effective therapeutic strategy against 
these inflammatory diseases (13-15). 
Canakinumb is a monoclonal antibody 
specifically targeting IL-1β. Two piv-
otal clinical studies have reported the 
efficacy of canakinumab in treating ac-
tive SJIA (13, 16). Moreover, case re-
ports on successful use of canakinumab 
in treatment of AOSD have been pub-
lished (14, 17-19). The objective of the 
present analysis was to describe the ef-
ficacy, safety, and exposure-response 
relationship of canakinumab in a sub-
group of SJIA patients ≥16 years of age 
(older adolescents and young adults), 
who are considered as representative 
of AOSD patients, and to compare this 
patient subgroup with those of children 
and young adolescents with SJIA using 
a pooled analysis of the pivotal SJIA 
studies of canakinumab. 
Materials and methods
Study design and patient population
This was a pooled subgroup analysis 
wherein data on canakinumab-treated 
patients were pooled from 4 SJIA stud-
ies, study designs for which have been 
published earlier (13, 16, 20). Brief 
description of the 4 studies is pro-
vided (Supplementary figure). Study 
1 (NCT00886769) was a phase 3, ran-
domised, double-blind, placebo-con-
trolled study conducted in SJIA patients 
who received either single subcutaneous 
(s.c.) doses of canakinumab at 4 mg/
kg (maximum of 300 mg) or placebo. 
Study 2 (NCT00889863), a phase 3 piv-
otal study, included two parts: Part I was 
an open-label, steroid-tapering study in 
which patients with SJIA received s.c. 
canakinumab 4 mg/kg (maximum dose 
of 300 mg) every 4 weeks, for up to 8 
months. Part II was a double-blind, pla-
cebo-controlled study that assessed flare 
prevention. Study 3 (NCT00891046) 
was a phase 3, open-label extension 
study, that enrolled SJIA patients who 
had received canakinumab in either 
Study 1 or Study 2 (Cohort 1) with an 
additional cohort of canakinumab-naïve 
patients (Cohort 2). Patients in both the 
cohorts were treated with s.c. canaki-
numab 4 mg/kg every 4 weeks for 12 
weeks and were included in pooled ef-
ficacy analyses. The study continued 
up to Week 217 with the possibility 
to reduce the dose to 2 mg/kg every 4 
weeks in patients who were steroid free. 
For Cohort 2 patients, no dose reduction 
could occur until 6 months of treatment. 
Study 4 (NCT00426218) was a phase 2, 
multicenter, open-label, uncontrolled, 
2-stage, dose-ranging study (0.5–9 mg/
kg) that evaluated the safety, tolerabil-
ity, immunogenicity, pharmacokinetics, 
and efficacy of repeated doses of canak-
inumab in patients with active SJIA.
Common inclusion criteria (with some 
differences among studies) were as fol-
lows: patients diagnosed with SJIA us-
ing the International League Against 
Rheumatism (ILAR) classification crite-
ria (21) confirmed at least 2 months be-
fore enrolment and disease onset at <16 
years of age, with at least 2 joints with 
active arthritis, documented spiking, in-
termittent fever for at least 1 day during 
the screening period and C-reactive pro-
tein (CRP) levels >30 mg/L (13, 16, 20). 
Patients were excluded if they were di-
agnosed with an active macrophage acti-
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vation syndrome (MAS) within the pre-
vious 6 months, had received treatment 
with another biologic agent or disease-
modifying drug (without a washout of 
≥5 half-lives), had active tuberculosis, 
human immunodeficiency virus, or hep-
atitis B or C infection, or had received 
live-virus vaccination within 3 months 
before enrolment (13, 16). 
Assessment and outcome measures
• Efficacy assessments
Data from patients who had received at 
least one dose of 4 mg/kg canakinumab 
in 3 studies (Study 1, 2 and 3) were 
pooled and included in the analysis for 
efficacy outcomes. Canakinumab treat-
ed patients were retrospectively catego-
rised in the 3 groups based on age at 
the time of enrolment: 2 to <12 years 
(children), 12 to <16 years (young ado-
lescents) and ≥16 years (older adoles-
cents and young adults, representing 
AOSD population). Efficacy data up to 
12 weeks of exposure were analysed, 
as this duration constituted data from 
canakinumab treated patients on a sta-
ble dose, without adjustment of other 
impactful comedication including ster-
oids (Study 2). Patients were evaluated 
for improvement in efficacy outcome 
measures including adapted American 
College of Rheumatology (aACR) pae-
diatric responses (ACR30/50/70/90/100 
response criteria), defined as absence 
of fever plus improvements of ≥30%, 
≥50%, ≥70%, ≥90%, and 100%, re-
spectively, from baseline in at least 
three of the six response variables and 
>30% worsening in no more than one 
of the six variables (13, 16), and ju-
venile idiopathic arthritis (JIA) ACR 
30/50/70/90/100 responses, defined as 
improvements of ≥30%, ≥50%, ≥70%, 
≥90%, and 100%, respectively from 
baseline in at least three of the six vari-
ables with no more than one of the six 
variables worsening by >30%.
ACR response (aACR or JIA ACR) 
variables included: number of joints 
with active arthritis, number of joints 
with limitation of motion, normalised 
CRP values (normal range of 0-10 
mg/L), physician’s global assessment 
of disease activity (on a 100-mm vis-
ual-analog scale, with higher scores 
indicating more disease activity), par-
ent’s global assessment of patient’s 
overall well-being (on a 100-mm vis-
ual-analogue scale, with higher scores 
indicating worse overall well-being), 
Childhood Health Assessment Ques-
tionnaire (CHAQ disability score; on 
a scale of 0 to 3, with higher scores 
indicating greater disability), absence 
of intermittent fever due to SJIA (body 
temperature ≤38°C) during the preced-
ing week, and 28-point disease activity 
score (DAS-28) CRP (based on num-
ber of tender and swollen joints from 
a 28 joints list) at Day 15 and Day 85. 
• Safety
Safety data of patients were collected 
from all 4 SJIA studies. Safety assess-
ments included collection of data on 
adverse events (AEs), AEs leading to 
discontinuation, serious adverse events 
(SAEs), and AEs of special interest. 
Safety events were described for the 3 
subgroups defined post hoc. 
• Pharmacokinetics and 
  exposure-response analysis
To compare adequacy of dosing and ex-
posure in older adolescents and young 
adults compared with children and 
young adolescents, drug concentra-
tion data of patients were pooled from 
all 4 SJIA studies for pharmacokinetic 
analysis. Serum samples of patients 
were collected at baseline and during 
treatment. Population pharmacokinet-
ics and exposure-response modeling 
were performed with dose, age, and 
weight as covariates. Pharmacokinetics 
concentrations in different age groups 
of SJIA patients over 12 weeks of treat-
ment were predicted using pharmacoki-
netics modeling. Steady-state exposure 
metrics, including trough concentration 
(CMINss), peak concentration (CMAXss), 
and area under the plasma concentra-
tion-time curve (AUCss) were derived 
from the model for the 3 age sub groups.
Statistical analysis
Efficacy and safety data were analysed 
using SAS v. 9.2 statistical package with 
predetermined age cut-offs to compare 
the efficacy and safety among the dif-
ferent age groups. Continuous variables 
were summarised by mean, standard 
deviation (SD), median, minimum, and 
maximum. Categorical variables were 
summarised by absolute frequencies 
and percentages. Baseline characteris-
tics were summarised using descriptive 
statistics. No formal statistical testing 
was performed to assess efficacy differ-
ences between subgroups.
Results
Demographic and baseline 
characteristics
A total of 301 patients were analysed 
for efficacy outcomes including 216 
children (age, 2 to <12 years), 56 young 
adolescents (age, 12 to <16 years) and 
29 older adolescents and young adults 
(age, ≥16 years). Baseline demographic 
and disease characteristics by age group 
are summarised in Table I. Overall, the 
baseline characteristics were well bal-
anced across all age groups. Gender 
distribution was similar in each age 
group. Most patients were Caucasian 
and approximately one-third of the 
patients were steroid-free. The pat-
tern of arthritis was similar across all 
age groups, except the proportion of 
patients with polyarthritis was higher 
in older adolescents and young adults. 
Systemic features after initial 6 months 
of disease were seen more frequently in 
older adolescents and young adults.
Efficacy outcomes
The efficacy parameters across the 3 
age groups were largely comparable. 
aACR paediatric responses to canaki-
numab treatment were rapid in all age 
groups; at Day 15, at least 50% of pa-
tients in each age group had aACR ≥70 
responses (Fig. 1). The response seen 
at Day 15 was maintained or improved 
over time until at Day 85 (Fig. 1). Simi-
lar results were observed for JIA ACR 
responses. At Day 15, at least 50% of 
patients from each age group (51.4%, 
58.9% and 65.5 % for children, young 
adolescents and older adolescents and 
young adults, respectively) had JIA 
ACR ≥70 responses and showed im-
provements (57.9%, 66.7% and 66.7% 
for children, young adolescents and 
older adolescents and young adults, re-
spectively) at Day 85.
Table II shows changes over time in 
ACR variables and clinical features for 
the patients. At baseline, the median 
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number of active joints was 8.0 in each 
age group. At Day 15, the median num-
ber of active joints ranged from 1 to 2 
and at Day 85 medians ranged from 0 
to 0.5 in all age groups. At Day 15, me-
dian percentage changes of active joints 
from baseline were -69.80 in children, 
-88.20 in young adolescents and -90.90 
in older adolescents and young adults. 
At Day 85, median percentage changes 
from baseline were -100.00 in chil-
dren, -100.00 in young adolescents and 
-98.10 in older adolescents and young 
adults, respectively. The median chang-
es in the number of joints with limita-
tion of motion were greater in young 
adolescents and older adolescents and 
young adults than in children. At Day 
Table I. Baseline demographic and disease characteristics by age group (efficacy set).
Characteristic Children Young Older adolescents
 N=216 adolescents  and young adults
  N=56  N=29
Female, n (%) 125 (57.9) 34 (60.7) 16 (55.2)
Age, mean (SD), years 6.3 (2.71) 13.3 (1.18)  17.1 (0.95)
Caucasian, n (%) 190 (88.0)  46 (82.1) 26 (89.7)
Disease duration, n (%)   
    ≤6 months 48 (22.2) 6 (10.7) 1 (3.4)
    >6 months to < 4 years 119 (55.1) 23 (41.1) 8 (27.6)
    ≥4 years 49 (22.7) 27 (48.2) 20 (69.0)
Patients on steroid, n (%) 146 (67.6) 35 (62.5) 18 (62.1)
Patients on NSAID, n (%) 121 (56.0) 30 (53.6) 12 (41.4)
Patients on methotrexate, n (%) 116 (53.7) 22 (39.3) 12 (41.4)
Children (2 – <12 years), young adolescents (12 – <16 years), older adolescents and young adults (≥16 
years).
N: total number of  patients in  each age  group; n: number of patients in each category of baseline 
characteristics.
NSAID: non-steroidal anti-inflammatory drugs; SD: standard deviation. 
Fig. 1. Response to treatment by age groups (efficacy set). Number of patients decreased at Day 85 because in one of the pooled studies, ACR assessments 
were not available in Cohort 2 patients at Day 85. ACR: American College of Rheumatology.
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15, medians in all age groups ranged 
from 1.5 to 2.0 and at Day 85 median 
values were same (1 in each age group) 
(Table II). The changes in DAS-28 
(CRP) scores were similar in all 3 age 
groups at Day 15; median changes from 
baseline were -2.10 in children, -2.53 in 
young adolescents, and -2.37 in older 
adolescents and young adults. Median 
changes from baseline at Day 85 were 
also similar between young adoles-
cents and older adolescents and young 
adults (-3.76 and -3.50, respectively), 
but smaller in children (-2.64). Absence 
of fever was seen early in all 3 groups. 
By Day 15, absence of intermittent fe-
ver was observed in 85.8%-96.4% of 
patients, with minimal difference be-
tween age groups. The median CRP 
levels rapidly decreased from baseline 
to Day 15 and remained low at Day 85 
in all age groups (Table II). The median 
values of physician’s global assessment 
of disease activity, parent’s or patient’s 
global assessment of patient’s overall 
wellbeing and CHAQ disability score 
decreased in all age groups at Day 15 
and Day 85 (Table II). 
Safety
In total, 324 patients were analysed 
for safety including 233 children, 60 
young adolescents and 31 older adoles-
cents and young adults. The mean (SD) 
number of doses administered were 
27.5 (22.01), 21.8 (16.84) and 30.3 
(23.77) in children, young adolescents 
and older adolescents and young adults, 
respectively. Table III summarises AEs 
by age groups. The most commonly re-
ported AEs in children, young adoles-
cents and older adolescents and young 
adults were infections and infestations, 
gastrointestinal disorders, and muscu-
loskeletal and connective tissue disor-
ders (Table III). Infections of the upper 
respiratory tract were among the most 
frequent AEs in all age groups, notably 
nasopharyngitis, upper respiratory tract 
infection, rhinitis (less frequent in the 
young adolescents), and cough (more 
common in children). Liver injury (he-
patic transaminases and bilirubin el-
evations) was reported as a study drug-
related AE in 35 (15.0%) children, 
10 (16.7%) young adolescents and 9 
(29.0%) older adolescents and young 
adults. One patient (13-year-old male) 
from the young adolescents group died 
because of pulmonary hypertension 
that was associated with MAS. SAEs 
were most commonly related to the 
underlying disease, such as flares or 
worsening of disease. The two most 
common SAEs in all 3 age groups were 
flare of SJIA and histiocytosis haema-
tophagic, also known as MAS (Table 
III). The MAS events were approxi-
mately twice as common in older ado-
Table II. Changes over time in ACR variables and DAS28-CRP by age groups (efficacy set).
 Baseline Day 15 Day 85
 Children Young Older Children Young Older Children Young Older
 N=216 adolescents adolescents N=216 adolescents adolescents N=216 adolescents adolescents
  N=56 and young  N=56 and young  N=56 and young
   adults   adults   adults
   N=29   N=29   N=29
Number of active joints n=216 n=56 n=29 n=211 n=54 n=28 n=100 n=20 n=16
   Median  (range) 8.0 (0 - 66) 8.0 (2 - 55) 8.0 (0 - 58) 2.0 (0 - 59) 1.5 (0 - 43) 1.0 (0 - 53) 0.0 (0 - 40) 0.0 (0 - 12) 0.5 (0 - 23)
Number of joints with limitation of motion n=216 n=56 n=29 n=211 n=54 n=28 n=100 n=20 n=16
   Median (range) 7.0 (0 - 62) 7.5 (0 - 55) 7.0 (0 - 56) 2.0 (0 - 65) 2.0 (0 - 43) 1.5 (0 - 55) 1.0 (0 - 67) 1.0 (0 - 33) 1.0 (0 - 55)
C-reactive protein levels, (mg/L) n=216 n=56 n=28 n=211 n=55 n=26 n=168 n=45 n=23
   Median (range) 133.90 149.00 104.70 12.00 10.00 4.50 9.75 8.40 7.80
 (0.0 - 800.0)  (3.0 - 683.3)  (1.6 - 651.2)  (0.0 - 633.3)  (0.0 - 436.7)  (0.6 - 182.2)  (0.0 - 386.7)  (0.0 - 458.3)  (0.8 - 110.6)
Score for physician’s global assessment n=216 n=56 n=29 n=210 n=55 n=28 n=100 n=20 n=16 
   of disease activity (mm,VAS) 
   Median (range) 64.0 (1 - 100) 62.5 (1 - 100) 63.0 (28 - 100) 18.0 (0 -100) 10.0 (0 - 97) 12.0 (0 - 76) 2.5 (0 - 100) 3.0 (0 - 47) 3.5 (0 - 72)
Score for parent’s global assessment of  n=216 n=55 n=29 n=209 n=54 n=27 n=99 n=20 n=16
   patient’s overall well-being (mm,VAS) 
   Median (range) 60.0 (0 - 100) 60.0 (0 - 98) 59.0 (0 - 98) 20.0 (0 - 100) 17.0 (0 - 89) 10.0 (0 - 89) 5.0 (0 - 98) 2.0 (0 - 95) 6.5 (0 - 80)
CHAQ disability score n=216 n=55 n=29 n=209 n=54 n=27 n=99 n=20 n=16
Median (range) 1.63 1.75 1.63 0.63 0.13 0.38  0.25 0.06 0.25
 (0.0 - 3.0)  (0.0 - 3.0)  (0.0 - 2.8)  (0.0 - 3.0)  (0.0 - 2.9)  (0.0 - 2.6)  (0.0 - 3.0)  (0.0 - 2.1)  (0.0 - 2.6)
Absence of intermittent fever due to  21.9 (47/215) 21.4 (12/56) 13.8 (4/29) 85.8 (181/211) 96.4 (53/55) 96.4 (27/28) 97.0 (164/169) 97.9 (47/48) 100 (25/25)
    SJIA, % (n/m) 
DAS28-CRP n=216 n=55 n=28 n=208 n=53 n=26 n=91 n=20 n=15
Median (range) 5.220 5.310 5.135 2.775 2.850 2.420 2.050 1.935 2.080
 (1.52 - 8.71) (2.80 - 8.84)  (1.76 - 8.17)  (0.96 - 8.45)  (1.16 - 8.54)  (1.25 - 7.49)  (0.96 - 7.19)  (1.03 - 5.60)  (1.37 - 5.79)
Children (2 – <12 years), young adolescents (12 – <16 years), older adolescents and young adults (≥16 years).  
N: total number of patients in each age group; n: number of patients assessed for ACR variables; m: number of patients with an assessment in the time period; 
ACR: American College of Rheumatology; CHAQ: Childhood Health Assessment Questionnaire; DAS-28: disease activity score (28-point); SJIA: systemic 
juvenile idiopathic arthritis; VAS: visual analogue scale.
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lescents and young adults and young 
adolescents compared with children 
(Table III). Analysis of MAS events 
showed that there was no increase in 
the rate MAS events in patients on 
canakinumab. Laboratory data collect-
ed by patient age group did not show 
any notable differences in safety and 
tolerability in adult patients as com-
pared with younger patients (children 
and young adolescents).
Pharmacokinetics and exposure-
response relationship by age groups
Pharmacokinetics analyses were con-
ducted in 233 children, 60 young ado-
lescents, and 31 older adolescents and 
young adults. Fig. 2 shows canaki-
numab exposure in SJIA patients from 
various age groups using different 
simulated metrics of exposure at the 
steady state (CMINss, CMAXss, and AUCss). 
Steady-state canakinumab exposure 
showed positive trends in median expo-
sure with increasing patient age, but the 
distributions significantly overlapped 
and were comparable across all age 
groups.
Discussion
Canakinumab has a well-established 
efficacy and safety profile in SJIA pa-
tients and is approved for its treatment 
in many countries. Canakinumab was 
recently also approved in Europe for 
treatment of AOSD patients.
We conducted this subgroup-analysis 
of pooled SJIA studies of canakinum-
ab to evaluate the efficacy, safety, and 
pharmacokinetics of canakinumab in 
different age groups of SJIA patients 
including children, young adoles-
cents, and older adolescents and young 
adults. This pooled analysis suggests 
that canakinumab has similar efficacy 
in older adolescents and young adults, 
comparable to its efficacy in children 
and young adolescents. The consist-
ent clinical benefits observed in older 
adolescents and young adults, who 
represent AOSD patients, were based 
on improvements observed in 3 differ-
ent domains representing both systemic 
and arthritic components of the disease, 
including: clinical, inflammatory labo-
ratory markers and quality of life (QoL) 
measures.
Clinical endpoints such as ACR crite-
ria, including aACR paediatric respons-
es and JIA ACR responses, improved 
rapidly and were maintained over 12 
weeks of treatment in the 3 different 
age groups. These improvements were 
largely consistent across the 3 age 
groups, with slightly higher responses 
Table III. Summary of adverse events and serious adverse events (safety set)#.
 Children, n (%) Young Older
 N=233 adolescents, n (%) adolescents
  N=60 and young adults, 
   n (%)
   N=31
AEs (at least 1) 202 (86.7) 53 (88.3) 27 (87.1)
AEs leading to study drug discontinuation 26 (11.2) 10 (16.7) 6 (19.4)
AEs most common    
Infections and infestations* 176 (75.5) 42 (70.0) 23 (74.2)
          Nasopharyngitis 68 (29.2) 18 (30.0) 13 (41.9)
          Upper respiratory tract infection 62 (26.6) 9 (15.0) 6 (19.4)
          Rhinitis 58 (24.9) 8 (13.3) 10 (32.3)
Gastrointestinal disorders* 122 (52.4) 32 (53.3) 18 (58.1)
          Vomiting 56 (24.0) 12 (20.0) 3 (9.7)
          Abdominal pain 51 (21.9) 9 (15.0) 7 (22.6)
          Diarrhoea 48 (20.6) 9 (15.0) 7 (22.6)
          Nausea 20 (8.6) 12 (20.0) 9 (29.0)
Musculoskeletal and connective tissue disorders* 119 (51.1) 33 (55.0) 16 (51.6)
         Juvenile idiopathic arthritis 55 (23.6) 17 (28.3) 6 (19.4)
         Arthralgia 49 (21.0) 17 (28.3) 8 (25.8)
         Arthritis 12 (5.2) 7 (11.7) 1 (3.2)
Skin and subcutaneous tissue disorders 108 (46.4) 25 (41.7) 13 (41.9)
          Eczema 32 (13.7) 6 (10.0) 2 (6.5)
          Rash 32 (13.7) 4 (6.7) 4 (12.9)
Respiratory, thoracic and mediastinal disorders 98 (42.1) 25 (41.7) 10 (32.3)
          Cough 70 (30.0) 13 (21.7) 6 (19.4)
          Oropharyngeal pain 42 (18.0) 10 (16.7) 5 (16.1)
          Rhinorrhoea 9 (3.9) 1 (1.7) 5 (16.1)
General disorders and administration site conditions§ 91 (39.1) 22 (36.7) 14 (45.2)
    Injury, poisoning and procedural complicationsα 71 (30.5) 17 (28.3) 5 (16.1)
    Nervous system disorders 64 (27.5) 24 (40.0) 12 (38.7)
    Investigations$ 55 (23.6) 15 (25.0) 9 (29.0) 
AEs of special interest   
   Thrombocytopenia 41 (17.6) 3 (5.0) 3 (9.7)
   Neutropenia 11 (4.7) 2 (3.3) 0
   Transaminase elevation 4 (1.7) 0  1 (3.2)
   Opportunistic infections 3 (1.3) 4 (6.7) 1 (3.3)
   Hepatitis 2 (0.9) 1 (1.7) 1 (3.2)
   Irritable bowel syndrome 1 (0.4) 0  0
SAE (at least 1)β 81 (34.8) 25 (41.7) 9 (29.0)
   Juvenile idiopathic arthritis 21 (9.0) 7 (11.7) 4 (12.9)
   Histiocytosis haematophagic (MAS) 12 (5.2) 7 (11.7) 3 (9.7)
   Pyrexia 7 (3.0) 5 (8.3) 1 (3.2)
   Gastroenteritis 5 (2.1) 3 (5.0) 0
   Cytomegalovirus infection 0  0  2 (6.5)
#Mean durations of exposure were 804.2, 637.3 and 888.8 days for children, young adolescents and 
older adolescents and young adults, respectively. 
*AEs by most commonly affected system organ class.
§In this category, commonly reported events (>2% in any age group) were pyrexia, fatigue, asthenia, 
drug ineffective, malaise, non-cardiac chest pain, peripheral swelling, influenza-like illness, feeling 
hot, and oedema.
αIn this category, commonly reported events (>2% in any age group) were arthropod bite, arthropod 
sting, contusion, fall, joint injury, hand fracture, ligament sprain, limb injury, skin abrasion, procedural 
pain, road traffic accident, and toxicity to various agents.
$Investigations primarily included increase of aspartate aminotransferase, alanine aminotransferase, 
blood triglycerides, C-reactive protein, hepatic enzyme, blood fibrinogen, gamma-glutamyltransferase, 
serum ferritin, and blood bilirubin.
βSAEs ≥5% in any age group, SAEs were not related to study drug treatment. 
AE: adverse events; SAEs: serious adverse events; MAS: macrophage activation syndrome; N: total 
number of patients in each age group.
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seen in older adolescents and young 
adults. These rapid responses observed 
at Day 15 were also consistently main-
tained at Day 85. These findings cor-
roborate previously published reports 
which showed that response to an IL-1 
receptor antagonist treatment was rap-
id and sustained in AOSD and SJIA 
patients, suggesting that IL-1 is a key 
cytokine in pathogenesis of these two 
diseases (3-4, 13, 22). Furthermore, a 
rapid and sustained decrease to a simi-
lar extent was observed in the 3 age 
groups in acute phase reactants as well 
as QoL measures. At Day 85, median 
CRP values in all age groups were less 
than 10 mg/L, which were within the 
normal range. Improvements observed 
in disability scores were also meaning-
ful at Day 85 and consistent across the 
3 age groups. No major differences in 
other efficacy measures were observed 
across all age groups. In fact, there 
was no indication of reduced efficacy 
with canakinumab in older adolescents 
and young adults at the 4 mg/kg dose 
every 4 weeks. These observations are 
consistent with case reports that have 
shown that canakinumab was success-
ful in controlling signs and symptoms 
of AOSD patients refractory to disease-
modifying anti-rheumatic drugs and 
short- to moderate-acting IL-1 block-
ade (14, 18). 
Patients from all three age groups 
showed broadly similar AE profiles: 
most frequent AEs included infections 
of the upper respiratory tract and gas-
trointestinal AEs. In general, older ado-
lescents and young adults (≥16 years) 
showed no major differences with re-
spect to AEs versus patients from the 
younger age groups. SAEs in the SJIA 
population were most commonly re-
lated to the underlying disease, such 
as flares or worsening of disease (JIA) 
or complications, most notably MAS 
(histiocytosis haematophagic) or in-
fections. The reported JIA and MAS 
events were not related to canakinumab 
treatment.
The results of these analyses support 
the concept of a Still’s disease con-
tinuum that includes both a paediatric 
or juvenile onset (SJIA) and adult onset 
(AOSD) form. SJIA and AOSD largely 
share the same pathophysiology and 
both diseases are highly responsive to 
IL-1β inhibition. Evidence suggests 
that SJIA and AOSD are also compa-
rable at the molecular level. Nirmala et 
al. showed that most genes that were 
down-regulated after canakinumab 
treatment in patients with SJIA were 
up-regulated in a majority of patients 
with active AOSD (2). 
A population-based pharmacokinetics-
binding model was built to evaluate 
adequacy of exposure with weight-
based dosing of canakinumab in older 
patients compared to younger patients. 
The model showed that overall, canak-
inumab exposures were comparable 
across all age groups including young 
adult SJIA patients. The analysis sup-
ports extrapolation of the efficacy 
of canakinumab in SJIA to the adult 
population of AOSD patients. Further-
more, the data support use of the same 
dose regimen for treatment of patients 
with AOSD (canakinumab 4 mg/kg s.c. 
monthly) as used for SJIA.
There are several limitations to this 
study. The post-hoc nature of the anal-
ysis along with small sample size in 
the young adult patients limits defini-
tive conclusions. Data was pooled for 
the first 12 weeks of treatment, which 
limits long term extrapolation of these 
results. Finally, small sample size also 
limits comprehensive understanding 
of the safety profile of canakinumab in 
AOSD patients who are older than the 
age range assessed in this analysis. In 
this analysis, the mean age of the adult 
patients was 17.1 years and therefore it 
does not address treatment with canaki-
numab across the full age spectrum of 
AOSD.
Overall, this pooled analysis from SJIA 
studies indicates that older adolescents 
and young adults SJIA patients (aged 
≥16 years at baseline of treatment con-
sidered to represent AOSD) exhibit 
similar efficacy, safety and exposure-
response relationship on a weight-
based dosing regimen to children and 
adolescent SJIA patients. These analy-
Fig. 2. Simulated steady-state exposure of canakinumab for SJIA patients stratified by age (pharmacokinetic analysis set).
The lower and upper end of boxes represent the 25th and 75th percentiles of distribution, the bold line in the box represents the median, and the whiskers 
5th and 95th percentiles of the data. Dots represent the outliers. Age given in years. N: the number of patients; SJIA: systemic juvenile idiopathic arthritis; 
AUCss: area under the plasma concentration-time curve; CMAXss: peak concentration; CMINss: trough concentration.
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ses suggest that canakinumab may 
be an effective therapy at a dose of 4 
mg/kg every 4 weeks in young-adult 
AOSD patients, as observed in SJIA 
patients. Further explorations with as-
sessment of canakinumab efficacy in 
patients with active AOSD are war-
ranted to confirm these findings.
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